[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Khalid et al., 2020 - Google Patents

Fibroblast growth factor receptor 3 mutation as a prognostic indicator in patients with urothelial carcinoma: a systematic review and meta-analysis

Khalid et al., 2020

View HTML
Document ID
14278834897377403626
Author
Khalid S
Basulaiman B
Emack J
Booth C
Duran I
Robinson A
Berman D
Smoragiewicz M
Amir E
Vera-Badillo F
Publication year
Publication venue
European Urology Open Science

External Links

Snippet

Background Fibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials. Objective We aimed to study the association between FGFR3 mutations and survival in urothelial …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis

Similar Documents

Publication Publication Date Title
Wang et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
Li et al. Adenosquamous carcinoma of the lung
Ferraldeschi et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate
Labianca et al. Colon cancer
Grivas et al. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches
Karapetis et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Safaee Ardekani et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis
Labianca et al. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up
Pichler et al. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor
Kolling et al. “Metastatic cancer of unknown primary” or “primary metastatic cancer”?
Falato et al. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
Thompson et al. Receptor tyrosine kinase expression profiles in canine cutaneous and subcutaneous mast cell tumors
Capdevila et al. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets
Bueno et al. Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (alliance)
Pagani et al. Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives
Seedor et al. Genetic landscape and emerging therapies in uveal melanoma
Hamada et al. Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour
Hutchins et al. Intratumoral stromal morphometry predicts disease recurrence but not response to 5‐fluorouracil—results from the QUASAR trial of colorectal cancer
Rutkowski et al. Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors: recommendations for patient selection, risk assessment, and molecular response monitoring
Bellmunt et al. Molecular targets on the horizon for kidney and urothelial cancer
Wu et al. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma
Bergot et al. Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
Allegrini et al. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab
Alshalalfa et al. Transcriptomic and clinical characterization of neuropeptide Y expression in localized and metastatic prostate cancer: identification of novel prostate cancer subtype with clinical implications
Di Leo et al. Topoisomerase II alpha as a marker predicting anthracyclines’ activity in early breast cancer patients: ready for the primetime?